CoChat

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States

Open access

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Aim: To assess adherence and discontinuation of injectable glucagon-like peptide-1 receptor agonists (GLP-1 RA) at 12 and 24 months among adult type 2 diabetes mellitus (T2DM) patients in the United States initiating GLP-1 RA using the administrative claims-based database, Optum Clinformatics ® Data Mart 7.1. Methods: A retrospective study was conducted from 01/2009 to 12/2017. Patients were required to be continuously enrolled for 12 months prior to their first GLP-1 RA prescription. Proportion of days covered (PDC) from prescription claims ≥ 0.80 defined adherence. Discontinuation was defined as a ≥ 90-day gap from the last date of GLP-1 RA supply to the first date of subsequent prescription claim. Results: A total of 4791 T2DM patients had ≥ 1 and 3907 had ≥ 2 GLP-1 RA prescription claims. 50.9% and 47.4% of patients were adherent at 12 and 24 months, respectively. Adherence was significantly higher among patients on weekly vs daily doses (p< 0.001). Median time to discontinuation was 13 months. The discontinuation rate was 47.7% and 70.1% at 12 and 24 months, respectively, with differences at 24 months for age and dosing frequency (p< 0.001 for both). Conclusion: Over half of T2DM patients initiating GLP-1 RA were non-adherent and the majority (70.1%) discontinued therapy by 24 months. Reasons for non-adherence and discontinuation merit further research. Keywords: GLP-1 RA, adherence, discontinuation, United States

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ppa.s277676

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study Design. The study period spans from January 1, 2009 until December 31, 2017. The index date was defined as the first claim for a prescription for GLP-1 RA monotherapy or dual therapy with metformin following an observed 12-month baseline period.
Figure 1 Study Design. The study period spans from January 1, 2009 until December 31, 2017. The index date was defined as the first claim for a prescription for GLP-1 RA monotherapy or dual therapy with metformin following an observed 12-month baseline period.CC BY-NC · PubMed Central
Figure 2 Proportion of Patients Who Were Adherent based on PDC ≥0.8 to GLP-1 RA Therapy, n=3907. Bar charts depicting percentage of patients who were adherent to GLP-1 RA therapy over the 12 months and 24 months study period. Proportions are assessed by overall total and the following stratifications: Age groups (<65, 65–75, 75+), Gender (Male, Female), Dosage (Daily Weekly). Adherence was only assessed among patients with 2 or more GLP-1 RA prescription fills. 12 months: *Age < 65 vs 65–74 years, p=0.01, **Male vs female p<0.01, ***Weekly vs daily p<0.01. 24 months (Cumulative): ‡Age <65 vs 65–74 years p<0.01, ±<65 years vs 75+years p=0.01, §Male vs female p<0.01, £weekly vs daily p<0.01.
Figure 2 Proportion of Patients Who Were Adherent based on PDC ≥0.8 to GLP-1 RA Therapy, n=3907. Bar charts depicting percentage of patients who were adherent to GLP-1 RA therapy over the 12 months and 24 months study period. Proportions are assessed by overall total and the following stratifications: Age groups (<65, 65–75, 75+), Gender (Male, Female), Dosage (Daily Weekly). Adherence was only assessed among patients with 2 or more GLP-1 RA prescription fills. 12 months: *Age < 65 vs 65–74 years, p=0.01, **Male vs female p<0.01, ***Weekly vs daily p<0.01. 24 months (Cumulative): ‡Age <65 vs 65–74 years p<0.01, ±<65 years vs 75+years p=0.01, §Male vs female p<0.01, £weekly vs daily p<0.01.CC BY-NC · PubMed Central
Figure 3 Time to Discontinuation of GLP-1 RAs, Kaplan–Meier Plot, n=4791. Kaplan–Meier plot of days until GLP-1 RA therapy discontinuation. Patients discontinued at median of 406 days (95% CI 386–424) after initiating therapy.
Figure 3 Time to Discontinuation of GLP-1 RAs, Kaplan–Meier Plot, n=4791. Kaplan–Meier plot of days until GLP-1 RA therapy discontinuation. Patients discontinued at median of 406 days (95% CI 386–424) after initiating therapy.CC BY-NC · PubMed Central
Figure 4 Proportion of Patients Who Discontinued GLP-1 RA Therapy, n=4791. Discontinuation was defined as a gap of >90 days from end of days of supply of GLP-1 RA claim and the first date of subsequent pescription claims (if any). Bar charts depicting percentage of patients who discontinued GLP-1 RA therapy over the 12 months and 24 months study period. Proportions are assessed by overall total and the following stratifications: Age groups (<65, 65–75, 75+), Gender (Male, Female), Dosage (Daily Weekly). Year 1: *Age <65 vs 75+ years p<0.01. Year 2: †Age <65 years vs 65–75 years; ‡Age <65 years vs 75 + years; £Weekly vs daily dosing, p<0.01.
Figure 4 Proportion of Patients Who Discontinued GLP-1 RA Therapy, n=4791. Discontinuation was defined as a gap of >90 days from end of days of supply of GLP-1 RA claim and the first date of subsequent pescription claims (if any). Bar charts depicting percentage of patients who discontinued GLP-1 RA therapy over the 12 months and 24 months study period. Proportions are assessed by overall total and the following stratifications: Age groups (<65, 65–75, 75+), Gender (Male, Female), Dosage (Daily Weekly). Year 1: *Age <65 vs 75+ years p<0.01. Year 2: †Age <65 years vs 65–75 years; ‡Age <65 years vs 75 + years; £Weekly vs daily dosing, p<0.01.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

4 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

Metadata

Authors
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • MSD (UK) Limited (United Kingdom) (GB)
Corresponding author
Weiss, Tracey
Venue
Patient Preference and Adherence
Published
2020-11
Volume
Volume 14
Pages
2337-2345
ISSN
1177-889X (ISSN-L)
OpenAlex
W3109831190
Cited by
126
References
37
Citations by year
2026: 34 · 2025: 39 · 2024: 28 · 2023: 13 · 2022: 7 · 2021: 5
FWCI
4.90
Type
journal article
Language
en
Open access
Locations
  • Patient Preference and Adherence (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
American Diabetes Association
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, type 2 diabetes, medication adherence, treatment discontinuation, proportion of days covered, dosing frequency, real-world evidence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.